Berenato Salvatore, Amato Ernesto, Fischer Alexander, Baldari Sergio
Biomedical Research Group, School of Engineering, Cardiff University, Cardiff, UK.
Section of Radiological Sciences, Department of Biomedical and Dental Sciences and Morpho-functional Imaging, University of Messina, Italy.
Phys Med. 2016 Oct;32(10):1259-1262. doi: 10.1016/j.ejmp.2016.09.012. Epub 2016 Sep 19.
Internal dosimetry is a fundamental instrument for the personalization of nuclear medicine therapies, to maximize the therapeutic effect while minimizing the radiation burden to other organs. Three-dimensional (3D) dosimetry can quantify the impact of heterogeneous radiopharmaceutical distributions in organs, lesions and tissues. We analysed the influence of radionuclide voxel S factors in 3D dosimetry of In, Lu and Y, the most used radionuclides in Peptide Receptor Radionuclide Therapy (PRRT). Calculations were carried out for kidneys on a workstation equipped with a software for 3D dosimetry (Imalytics STRATOS, Philips AG), adopting a computational anthropomorphic phantom and, retrospectively, the SPECT-CT image series of a clinical case of PRRT. Two sets of voxel S factors were adopted: the pre-loaded Philips kernels, calculated by direct Monte Carlo simulation, and the ones calculated through a previously proposed analytical approach. Philips In kernel did not account for mono-energetic Auger or Conversion electrons. Results indicate a difference of about -32% in voxel S factors for In in 4.42mm voxel size and around -35% in 4.80mm voxel size, particularly self-dose values; this lead to significant shift in dose histograms and average doses. For Lu and Y, differences are about 2% and 12% for 4.42mm voxels and about -8% and 9% for 4.80mm voxels, respectively, attributable to the different calculation methods of the voxel S factors; this does not lead to significant discrepancies between the two dose histograms. Consequently, voxel S factors must account accurately for all radiations emitted by the nuclide.
体内剂量测定是核医学治疗个体化的一项基本手段,旨在在使对其他器官的辐射负担最小化的同时最大化治疗效果。三维(3D)剂量测定可以量化放射性药物在器官、病变和组织中的非均匀分布的影响。我们分析了放射性核素体素S因子在肽受体放射性核素治疗(PRRT)中最常用的放射性核素铟(In)、镥(Lu)和钇(Y)的3D剂量测定中的影响。在配备有3D剂量测定软件(Imalytics STRATOS,飞利浦公司)的工作站上,采用计算人体模型,并回顾性地使用PRRT临床病例的SPECT-CT图像系列,对肾脏进行了计算。采用了两组体素S因子:预加载的飞利浦内核,通过直接蒙特卡罗模拟计算得出;以及通过先前提出的分析方法计算得出的体素S因子。飞利浦铟内核未考虑单能俄歇电子或内转换电子。结果表明,对于4.42mm体素大小的铟,体素S因子的差异约为-32%,对于4.80mm体素大小的铟,差异约为-35%,特别是自身剂量值;这导致剂量直方图和平均剂量有显著偏移。对于镥和钇,4.42mm体素的差异分别约为2%和12%,4.80mm体素的差异分别约为-8%和9%,这归因于体素S因子的不同计算方法;这并未导致两个剂量直方图之间出现显著差异。因此,体素S因子必须准确考虑核素发射的所有辐射。